

## HOTLINE: Effective August 19, 2019

New Test 3001869 Myasthenia Gravis Reflexive Panel MG R PAN



## Additional Technical Information

Methodology: Quantitative Radioimmunoassay/Semi-Quantitative Flow Cytometry

**Performed:** Sun-Sat **Reported:** 3-8 days

Specimen Required: Collect: Serum Separator Tube (SST).

Specimen Preparation: Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard

Transport Tube. (Min: 0.5 mL)

Storage/Transport Temperature: Refrigerated.

<u>Unacceptable Conditions:</u> Contaminated, hemolyzed, or severely lipemic specimens.

Stability (collection to initiation of testing): After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month

(avoid repeated freeze/thaw cycles)

## **Reference Interval:**

Test Number	Components	Reference Interval	
0080009	Acetylcholine Receptor Binding Antibody	Negative	0.0-0.4 nmol/L
		Positive	0.5 nmol/L or greater
0099580	Acetylcholine Receptor Blocking Antibody	Effective November 18, 2013	
		Negative:	0-26% blocking
		Indeterminate:	27-41% blocking
		Positive:	42% or greater blocking
0099521	Acetylcholine Receptor Modulating Antibody	Effective August 20, 2012	
		Negative	0-45% modulating
		Positive	46% or greater modulating
3001576	Muscle-Specific Kinase (MuSK) Antibody, IgG	Negative	0.00-0.03 nmol/L
		Positive	0.04 nmol/L or greater

**Interpretive Data:** Approximately 85-90 percent of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibodies. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair binding of acetylcholine to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15 percent of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibodies.

See Compliance Statement B: www.aruplab.com/CS

**Note:** If Acetylcholine Receptor Binding Antibody result is greater than 0.4 nmol/L or Acetylcholine Receptor Blocking Antibody result is greater than 26 percent, then Acetylcholine Receptor Modulating Antibody (ARUP test code 0099521) will be added. If Acetylcholine Receptor Binding Antibody result is less than or equal to 0.4 nmol/L, then Muscle-Specific Kinase (MuSK) Ab, IgG (ARUP test code 3001576) will be added. Additional charges apply.

**CPT Code(s):** 83519; 83516; if reflexed, add 83516, 83519

New York DOH Approved.

**HOTLINE NOTE:** Refer to the Test Mix Addendum for interface build information.